Recent compelling publications from us and others demonstrate that FABP5 inhibitors based on the truxillic-acid monoester (TAMEs) scaffold have a profound effect on PCa progression [19,24,26,28,29,30]. The gene discussed is FABP5; the disease is posterior cortical atrophy.